NCT05874921From ClinicalTrials.govRecruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Urothelial Carcinoma
Urothelial Carcinoma Recurrent
Urothelial Carcinoma Ureter
Urothelial Carcinoma Ureter Recurrent
Urothelial Cancer of Renal Pelvis
Urothelial Carcinoma of the Renal Pelvis and Ureter
Carcinoma, Transitional Cell
Transitional Cell Carcinoma of Renal Pelvis

At a glance

Phase: Phase not stated
Study type: Observational
Sponsor: UroGen Pharma Ltd.
Enrolment target: 450
Started: 17 November 2023
Main results due: October 2027
Study sites: 22
Registry updated: 29 September 2026

Can you take part?

Aged 18 years and over.
Open to any sex.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Inclusion Criteria:

* Adults \>18 years old and capable of giving informed consent.
* Diagnosis of UTUC.
* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).

Exclusion Criteria:

* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).
* Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).
* Pregnancy or lactation.
* Unable to comply with protocol requirements (for prospective data capture).
* Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

Study sites(22)

Providence St. Johns Health Center
Santa Monica, California, United States
Recruiting
University of Florida
Gainesville, Florida, United States
Recruiting
Mount Sinai Medical Center of Florida, Inc.
Miami, Florida, United States
Recruiting
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa, Florida, United States
Recruiting
Northwestern University
Chicago, Illinois, United States
Recruiting
Indiana University
Indianapolis, Indiana, United States
Recruiting
The State University of Iowa
Iowa City, Iowa, United States
Recruiting
Chesapeake Urology
Baltimore, Maryland, United States
Recruiting
Johns Hopkins Medical Center
Baltimore, Maryland, United States
Recruiting
Mass General Brigham
Boston, Massachusetts, United States
Recruiting
Brigham and Women's Hospital
Boston, Massachusetts, United States
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Recruiting
University of Missouri
Columbia, Missouri, United States
Recruiting
Rutgers
New Brunswick, New Jersey, United States
Recruiting
The Feinstein Institutes for Medical Research
Lake Success, New York, United States
Recruiting
NYU Grossman School of Medicine
New York, New York, United States
Recruiting
SUNY Upstate
Syracuse, New York, United States
Recruiting
The University of North Carolina Chapel Hill
Chapel Hill, North Carolina, United States
Recruiting
Ohio State University
Columbus, Ohio, United States
Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Recruiting
UT Southwestern Medical Center
Dallas, Texas, United States
Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Recruiting

Showing 22 of 22 sites. 22 of the 22 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT05874921. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me